Moore Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Moore Capital Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-175,000	Closed	-$1.04M	–	611
2020 Q3	$1.04M	Hold	175,000	–	–	0.02%	293
2020 Q2	$466K	Hold	175,000	–	–	0.01%	226
2020 Q1	$341K	Buy	175,000 +125,000	+250%	+$538K	0.01%	142
2019 Q4	$353K	Hold	50,000	–	–	0.01%	224
2019 Q3	$492K	Sell	50,000 -50,000	-50%	-$562K	0.02%	256
2019 Q2	$1.14M	Hold	100,000	–	–	0.03%	246
2019 Q1	$1M	Buy	+100,000	New	+$1.28M	0.03%	236

Other funds holding XERS

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

Moore Capital Management's XERS Position: Q4 2020 in Review

Moore Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q4 2020, closing a stake of 175,000 shares — an estimated $1.04M sold.

Moore Capital Management first reported a position in XERS in Q1 2019 and held it in 7 quarters. The position peaked at $1.14M in Q2 2019. 96 funds tracked by Wall St. Rank hold XERS as of Q4 2020.

Moore Capital Management reported no remaining Xeris Biopharma Holdings position as of Q4 2020 after selling out during the quarter.
Moore Capital Management sold 175,000 Xeris Biopharma Holdings shares in Q4 2020, an estimated $1.04M.
Moore Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2019 and held it in 7 quarters.
Moore Capital Management's Xeris Biopharma Holdings position peaked at $1.14M in Q2 2019.
96 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2020.

Based on Moore Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.